A single dose of CJC-1295 (long-acting GHRH analog) maintained elevated pulsatile GH secretion for several days in healthy humans with dose-dependent duration — validating once-weekly or less frequent GH-axis restoration.
Key findingSingle SC injection of CJC-1295 maintained elevated pulsatile GH secretion and IGF-1 for days in healthy subjects, with dose-dependent duration of act
What the researchers found
Single SC injection of CJC-1295 maintained elevated pulsatile GH secretion and IGF-1 for days in healthy subjects, with dose-dependent duration of action — validating once-weekly (or less) dosing for sustained GH-axis restoration in the first human clinical trial.
Why it matters
Relevant for cjc-1295, hormone-optimization.
How the study worked
clinical-trial study on cjc-1295, hormone-optimization.
What this study cannot tell us
See abstract.
How to read the evidence
strong evidence.
When this study was published
Published in 2006.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
- Clinical translation to evaluate.
Common questions
What was studied?
What was found?
Read the original research
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.
The Journal of clinical endocrinology and metabolism, 91(12), 4792-7
Citation
Ionescu, Madalina; Frohman, Lawrence A. (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.. The Journal of clinical endocrinology and metabolism, 91(12), 4792-7.